EU regulator backs GSK’s rubella virus vaccine for use in adults aged 50-59 years
The European Union’s health regulator has recommended expanding the use of GSK’s respiratory syncytial virus (RSV) vaccine to adults aged 50-59 years. The vaccine, called Arexvy, was approved by the US Food and Drug Administration in June.
POPULAR POSTS
Poland prepares for peaking floods
September 20, 2024
Italy evacuates thousands as Boris hits the north
September 20, 2024
China and the US race to tame nuclear fusion for clean energy
September 20, 2024
Florence Pugh speaks about first acting break
September 20, 2024
LIVE STREAM